AR054084A1 - Derivados de indolcarboxamida y composiciones farmaceuticas que los contienen - Google Patents
Derivados de indolcarboxamida y composiciones farmaceuticas que los contienenInfo
- Publication number
- AR054084A1 AR054084A1 ARP050103900A ARP050103900A AR054084A1 AR 054084 A1 AR054084 A1 AR 054084A1 AR P050103900 A ARP050103900 A AR P050103900A AR P050103900 A ARP050103900 A AR P050103900A AR 054084 A1 AR054084 A1 AR 054084A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- substituted
- heterocycloalkyl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Compuesto de indolcarboxamida, inhibidor de la actividad quinasa. Composicion farmacéutica que lo comprende y su uso para preparar un medicamento para tratar un trastorno debido a una actividad inadecuada de IKK2, como ser artritis reumatoide, enfermedad inflamatoria del intestino, asma, COPD (enfermedad pulmonar obstructiva cronica), osteoartritis, osteoporosis, psoriasis, dermatitis atopica, lesiones cutáneas inducidas por radiacion ultravioleta, lupus sistémico eritermatoso, esclerosis multiple, artritis psoriásica, espondilitis anquilosante, rechazo de tejidos, rechazo de organos, enfermedad de Alzheimer, apoplejía, aterosclerosis, reestenosis, diabetes, glomerulonefritis, enfermedad de Hodgkins, caquexia, inflamacion asociada con infecciones y ciertas infecciones víricas, incluyendo el síndrome de inmunodeficiencia adquirida (SIDA), síndrome de insuficiencia respiratoria en adultos y ataxia telangiectasia. Reivindicacion 1: Un compuesto de indolcarboxamida, caracterizado porque tiene la formula (1), en la que: R1 es H, halogeno o un grupo -YZ; R2 es H, fluor o cloro; R3 es H, fluor o cloro; Y es un enlace, alquileno C1-6, alquenileno C2-6 o alquinileno C2-6; Z es arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido, donde dichos arilo y heteroarilo están opcionalmente sustituidos con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en: halo, -CN, -N(Rb)SO2Re, -N(Rb)C(O)Ra, -C(O)NRaRb, - C(O)NRfRg, -C(O)H, -SO2Ri, -NRaRb, -SO2NRaRb, -SO2NRfRg, -ORc, -N(Rb)C(O)NRaRb, -N(Rb)C(O)NRfRg, -N(Rb)C(O)ORd, alquilo C1-6, alquilo C1-6 sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en: - NRaRb, cicloalquilo C3-6, fenilo, -ORc, heterocicloalquilo y heterocicloalquilo sustituido con OH, -C(O)NH2, o uno o dos grupos alquilo C1-6; haloalquilo C1-6, haloalquilo C1-6 sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en -NRaRb, cicloalquilo C3-6, fenilo, heterocicloalquilo y heterocicloalquilo sustituido con uno o dos grupos alquilo C16; heterocicloalquilo y heterocicloalquilo sustituido con uno o dos grupos alquilo C1-6; U es un enlace, alquileno C1-6 o alquenileno C2-6; V es fenilo, heteroarilo de 5 o 6 miembros, heterocicloalquilo de 5-7 miembros, cicloalquilo C5-7 o cicloalquenilo C5-7, cada uno de ellos está sustituido con -N(Rb)S(O)mR4, -S(O)mN(Rb)R4 o -S(O)mR4; m es 1 o 2; R4 es el grupo -X-R5; X es un enlace, alquileno C1-6, alquenileno C2-6, alquinileno C2-6, arilo, alquilenoC1-6-arilo, heteroarilo, alquilenoC1-6-heteroarilo, heterocicloalquilo, alquilenoC1-6-heterocicloalquilo, cicloalquilo C4-7, alquilenoC1-6- cicloalquiloC4-7, cicloalquenilo C5-7 o alquilenoC1-6-cicloalqueniloC5-7; R5 es -NRaRb, -ORj, heterocicloalquilo opcionalmente sustituido o heteroarilo opcionalmente sustituido, donde dichos heterocicloalquilo opcionalmente sustituido y heteroarilo opcionalmente sustituido están opcionalmente sustituidos con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en: halo, heteroarilo, oxo, -CN, -C(O)Ra, -N(Rb)SO2Re, -N(Rb)C(O)Ra, -NRaRb, -C(O)NRaRb, -C(O)NRfRg, - SO2NRaRb, -SO2NRfRg, -ORc, -C(O)ORc, -N(Rb)C(O)NRaRb, -N(Rb)C(O)NRfRg, -N(Rb)C(O)ORd, alquilo C1-6, alquilo C1-6 sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en: -NRaRb, -ORc, -C(O)NRaRb, - C(O)Rc, cicloalquilo C3-6, heterocicloalquilo y fenilo; haloalquilo C1-6, haloalquilo C1-6 sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en: -NRaRb, -ORc, -C(O)NRaRb, cicloalquilo C3-6, heterocicloalquilo y fenilo; heterocicloalquilo, heterocicloalquilo sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en: alquilo C1-6, halo, -ORc, haloalquilo, CN y -SO2Ri; fenilo y fenilo sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en: halo, -ORc, haloalquilo, -CN y -SO2Ri; cada Ra se selecciona independientemente entre el grupo que consiste en: H, ORh, alquenilo C2-6, alquinilo C2-6, alquilo C1-6, alquilo C1-6 sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste e: halo, -CN, -C(O)NH2, -NRkRk, -SO2Ri, -N(Rb)SO2Re, -C(O)ORb, -N(Rb)C(O)Rb, -ORc, -SRc, cicloalquilo C3- 7, haloalquilo C1-6, heterocicloalquilo, fenilo, fenolilo y heteroarilo; fenilo, fenilo sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en: halo, oxo, alquilo C1-6, haloalquilo C1-6, NH2, heteroarilo, -ORc y -NRfRg; heteroarilo, heteroarilo sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en: halo, oxo, alquilo C1-6, haloalquilo C1-6, NH2, heteroarilo, -ORc y -NRfRg; cicloalquilo C3- 7, cicloalquilo C3-7 sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en: halo, oxo, alquilo C1-6, haloalquilo C1-6, NH2, heteroarilo, -ORc y -NRfRg; heterocicloalquilo y heterocicloalquilo sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en: halo, oxo, alquilo C1-6, -CH2C(O)Rb, haloalquilo C1-6, -C(O)ORb, NH2. heteroarilo, -ORc y NRfRg; cada Rb se selecciona independientemente entre el grupo que consiste en: H, alquilo C1-6, alquilo C1-6 sustituido con un -ORc y cicloalquilo C3-7; cada Rc se selecciona independientemente entre el grupo que consiste en: H, alquilo C1-6, alquilo C1-6 sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en: OH, cicloalquilo C3-6, fenilo, heterocicloalquilo y heteroarilo; haloalquilo C1-6, haloalquilo C1-6 sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en: OH, cicloalquilo C3-6, fenilo, heterocicloalquilo y heteroarilo; cicloalquilo C3-7, cicloalquilo C3-7 sustituido con uno a tres grupos alquilo C1-3; heterocicloalquilo, heterocicloalquilo sustituido con uno a tres grupos alquilo C1-3; arilo, arilo sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en: halo, alquilo C1-3, haloalquilo C1-3 y OH; heteroarilo y heteroarilo sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en: halo, alquilo C1-3, haloalquilo C1-3 y OH; cada Rd es independientemente un alquilo C1-3 opcionalmente sustituido, donde dicho alquilo C1-3 está opcionalmente sustituido con uno a tres sustituyentes seleccionados entre el grupo que consiste en: cicloalquilo C3-6, heterocicloalquilo, fenilo opcionalmente sustituido y heteroarilo opcionalmente sustituido; donde dichos fenilo y heteroarilo están opcionalmente sustituidos con uno a tres sustituyentes seleccionados entre el grupo que consiste en: halo, alquilo C1-6 y cicloalquilo C3-6; cada Re se selecciona independientemente entre el grupo que consiste en: alquilo C1-6, alquilo C1-6 sustituido con un sustituyentes seleccionado entre el grupo que consiste en: fenilo, heteroarilo, heterocicloalquilo y NRaRb; fenilo, fenilo sustituido con uno a tres sustituyentes seleccionados entre el grupo que consiste en: halo, CN, alquilo C1-6, haloalquilo C16 y ORh; heteroarilo, heteroarilo sustituido con uno a tres sustituyentes seleccionados entre el grupo que consiste en: halo, CN, alquilo C1-6, haloalquilo C1-6 y -ORh; cicloalquilo C5-7; cicloalquilo C5-7 sustituido con uno a tres sustituyentes seleccionados entre el grupo que consiste en: halo, alquilo C1-6 y cicloalquilo C3-6; heterocicloalquilo y heterocicloalquilo sustituido con uno a tres sustituyentes seleccionados entre el grupo que consiste en: halo, alquilo C1-6 y cicloalquiloC3-6; Rf y Rg tomados junto con el átomo de nitrogeno al que están unidos forman un anillo que tiene de 5 a 7 átomos miembros donde dicho anillo contiene opcionalmente un heteroátomo más como un átomo miembro, estando dicho anillo saturado o insaturado pero no aromático y estando dicho anillo opcionalmente sustituido con uno o dos sustituyentes alquilo C1-3; cada Rh se selecciona independientemente entre el grupo que consiste en: H, alquilo C1-6 y haloalquilo C1-6; cada Ri se selecciona independientemente entre el grupo que consiste en: alquilo C1-3 y fenilo; Rj se selecciona entre el grupo que consiste en H, alquilo C1-6 opcionalmente sustituido, haloalquilo C1-6, heteroarilo y fenilo opcionalmente sustituido, donde dicho alquilo C1-6 opcionalmente sustituido está opcionalmente sustituido con uno o dos sustituyentes seleccionados cada uno independientemente entre los siguientes: hidroxi, alcoxi C1-6, -OCH2CH2N(CH3)2, metiltio, cicloalquilo C3-6, cicloalquilo C3-6 sustituido con un grupo alquilo C1-3; heterocicloalquilo, heterocicloalquilo sustituido con un alquilo C1-3, un grupo oxo o un grupo 4-flurobencilo, -NRkRk, heteroarilo, -NHC(O)CH3 y S(O)2Ri; donde dicho fenilo está opcionalmente sustituido con uno a tres sustituyentes seleccionados cada uno independientemente entre los siguientes: alcoxi C1-3, -NHC(O)CH3, -C(O)NH2, halo, CF3, -S(O)2Ri, -S(O)2NHRi, hidroxi, -alquilC1-3-NRkRk, -NRkRk, alquilo C1-3, heterocicloalquilo y heterocicloalquilo sustituido con un grupo - C(O)CH3; y cada Rk se selecciona independientemente entre H, alquilo C1-6, alquilo C1-6 sustituido con uno o dos grupos hidroxilo; fenilo y fenilo sustituido con un grupo alquilo C1-3; o una sal farmacéuticamente aceptable, solvato o polimorfo del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61176104P | 2004-09-21 | 2004-09-21 | |
US69545405P | 2005-06-30 | 2005-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR054084A1 true AR054084A1 (es) | 2007-06-06 |
Family
ID=36090636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050103900A AR054084A1 (es) | 2004-09-21 | 2005-09-20 | Derivados de indolcarboxamida y composiciones farmaceuticas que los contienen |
Country Status (16)
Country | Link |
---|---|
US (1) | US7858796B2 (es) |
EP (1) | EP1793826A4 (es) |
JP (1) | JP2008513500A (es) |
KR (1) | KR20070057969A (es) |
AR (1) | AR054084A1 (es) |
AU (1) | AU2005286795A1 (es) |
BR (1) | BRPI0515524A (es) |
CA (1) | CA2581180A1 (es) |
IL (1) | IL181877A0 (es) |
MA (1) | MA28912B1 (es) |
MX (1) | MX2007003283A (es) |
NO (1) | NO20071988L (es) |
PE (1) | PE20060748A1 (es) |
SG (1) | SG155932A1 (es) |
TW (1) | TW200626142A (es) |
WO (1) | WO2006034317A2 (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0400895D0 (en) * | 2004-01-15 | 2004-02-18 | Smithkline Beecham Corp | Chemical compounds |
TW200616967A (en) * | 2004-06-24 | 2006-06-01 | Smithkline Beecham Corp | Novel indazole carboxamides and their use |
WO2007005534A2 (en) * | 2005-06-30 | 2007-01-11 | Smithkline Beecham Corporation | Chemical compounds |
US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
JP2009516702A (ja) * | 2005-11-18 | 2009-04-23 | スミスクライン・ビーチャム・コーポレイション | 化合物 |
JP2009519968A (ja) * | 2005-12-16 | 2009-05-21 | スミスクライン・ビーチャム・コーポレイション | 化学物質 |
TWI403320B (zh) | 2005-12-16 | 2013-08-01 | Infinity Discovery Inc | 用於抑制bcl蛋白和結合夥伴間之交互作用的化合物及方法 |
AR065804A1 (es) * | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
JP5487214B2 (ja) | 2008-12-19 | 2014-05-07 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物 |
EP2370407B1 (en) * | 2008-12-19 | 2014-06-18 | Bristol-Myers Squibb Company | Carbazole and carboline kinase inhibitors |
WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
EP2566327B1 (en) | 2010-05-07 | 2017-03-29 | Glaxosmithkline LLC | Indoles |
EP2582668B1 (en) | 2010-06-16 | 2016-01-13 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
US9567339B2 (en) * | 2013-06-26 | 2017-02-14 | Abbvie Inc. | Primary carboxamides as BTK inhibitors |
KR102272792B1 (ko) | 2013-09-30 | 2021-07-05 | 광저우 이노케어 파마 테크 씨오., 엘티디. | Btk의 치환된 니코틴이미드 저해제 및 그의 제조 방법 및 암, 염증 및 자가면역 질환에의 용도 |
AR102426A1 (es) | 2014-10-24 | 2017-03-01 | Bristol Myers Squibb Co | Compuestos de indolcarboxamida como inhibidores de btk |
EP3365340B1 (en) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MD3377488T2 (ro) | 2015-11-19 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
SG11201805300QA (en) | 2015-12-22 | 2018-07-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
CA3028685A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US20180016260A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
ES2934230T3 (es) | 2016-12-22 | 2023-02-20 | Incyte Corp | Derivados de benzooxazol como inmunomoduladores |
US20180179179A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
FI3774791T3 (fi) | 2018-03-30 | 2023-03-21 | Incyte Corp | Heterosyklisiä yhdisteitä immunomodulaattoreina |
CN112752756A (zh) | 2018-05-11 | 2021-05-04 | 因赛特公司 | 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物 |
TW202115059A (zh) | 2019-08-09 | 2021-04-16 | 美商英塞特公司 | Pd—1/pd—l1抑制劑之鹽 |
AU2020357514A1 (en) | 2019-09-30 | 2022-04-07 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
WO2021096849A1 (en) | 2019-11-11 | 2021-05-20 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
IL302590A (en) | 2020-11-06 | 2023-07-01 | Incyte Corp | Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4775761A (en) * | 1983-08-22 | 1988-10-04 | Hoechst-Roussel Pharmaceuticals, Inc. | 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles |
US5256673A (en) * | 1983-11-25 | 1993-10-26 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Indole-3-yl-A-tetrahydropyridyl or piperidyl compounds |
DE3342632A1 (de) | 1983-11-25 | 1985-06-05 | Merck Patent Gmbh, 6100 Darmstadt | Indolderivate |
ES2059408T3 (es) | 1987-02-10 | 1994-11-16 | Abbott Lab | Un proceso para la preparacion de un compuesto. |
IE903206A1 (en) | 1989-09-07 | 1991-03-13 | Abbott Lab | Indole-, benzofuran-, and benzothiophene-containing¹lipoxygenase-inhibiting compounds |
US5330986A (en) * | 1992-11-24 | 1994-07-19 | Hoechst-Roussel Pharmaceuticals Inc. | Indole-7-carboxamide derivatives |
FR2701026B1 (fr) | 1993-02-02 | 1995-03-31 | Adir | Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
DE19500689A1 (de) | 1995-01-12 | 1996-07-18 | Merck Patent Gmbh | Indolpiperidin-Derivate |
US5846982A (en) | 1996-06-14 | 1998-12-08 | Eli Lilly And Company | Inhibition of serotonin reuptake |
EP1077213A3 (en) | 1996-06-14 | 2001-06-13 | Eli Lilly And Company | Inhibition of serotonin reuptake |
AR013669A1 (es) | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
DE19807993A1 (de) | 1998-02-26 | 1999-09-02 | Bayer Ag | Verwendung von ß-Carbolinderivaten zur Bekämpfung von TNF-alpha-abhängigen Krankheiten |
JP2002526500A (ja) * | 1998-09-18 | 2002-08-20 | ビーエーエスエフ アクチェンゲゼルシャフト | プロテインキナーゼ阻害剤としてのピロロピリミジン |
DE19928424A1 (de) | 1999-06-23 | 2000-12-28 | Aventis Pharma Gmbh | Substituierte Benzimidazole |
DE19951360A1 (de) | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituierte Indole |
US6245799B1 (en) * | 1999-11-08 | 2001-06-12 | American Home Products Corp | [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders |
EP1228065A1 (en) | 1999-11-08 | 2002-08-07 | Wyeth | (indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders |
GB0003154D0 (en) | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
EP1134221A1 (en) | 2000-03-15 | 2001-09-19 | Aventis Pharma Deutschland GmbH | Substituted beta-carbolines as lkB kinase inhibitors |
WO2001068648A1 (en) | 2000-03-15 | 2001-09-20 | Aventis Pharma Deutschland Gmbh | Substituted beta-carbolines with ikb-kinase inhibiting activity |
EP1209158A1 (en) | 2000-11-18 | 2002-05-29 | Aventis Pharma Deutschland GmbH | Substituted beta-carbolines |
US6627645B2 (en) | 2000-04-28 | 2003-09-30 | Acadia Pharmaceuticals, Inc. | Muscarinic agonists |
AU2001256714A1 (en) | 2000-05-15 | 2001-11-26 | Kissei Pharmaceutical Co. Ltd. | Water-based liquid preparation |
US6414013B1 (en) | 2000-06-19 | 2002-07-02 | Pharmacia & Upjohn S.P.A. | Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention |
WO2002014317A2 (en) | 2000-08-14 | 2002-02-21 | Ortho Mcneil Pharmaceutical, Inc. | Substituted pyrazoles |
US20030171413A1 (en) | 2000-08-17 | 2003-09-11 | Owen David Alan | Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatory disorders |
MXPA03001960A (es) * | 2000-09-06 | 2004-03-18 | Johnson & Johnson | Un metodo para tratar alergias. |
JP4272338B2 (ja) | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
ES2260300T3 (es) | 2000-10-03 | 2006-11-01 | Bristol-Myers Squibb Company | Compuestos tetraciclicos sustituidos con amino utiles como agentes antiinflamatorios y composiciones farmaceuticas que comprenden los mismos. |
US6869956B2 (en) * | 2000-10-03 | 2005-03-22 | Bristol-Myers Squibb Company | Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK) |
WO2002030423A1 (en) | 2000-10-12 | 2002-04-18 | Smithkline Beecham Corporation | NF-λB INHIBITORS |
WO2002030353A2 (en) | 2000-10-12 | 2002-04-18 | Smithkline Beecham Corporation | NF-λB INHIBITORS |
ES2305125T3 (es) | 2000-10-26 | 2008-11-01 | Amgen Inc. | Agentes anti-inflamatorios. |
JP2002193938A (ja) | 2000-12-01 | 2002-07-10 | Bayer Ag | 4−アリールピリジン誘導体 |
US7122544B2 (en) | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
JP4307073B2 (ja) | 2000-12-22 | 2009-08-05 | ワイス | 5−ヒドロキシトリプトアミン−6リガンドとしてのヘテロサイクルインダゾールおよびアザインダゾール化合物 |
CZ20032287A3 (cs) | 2001-02-01 | 2004-02-18 | Bristol-Myers Squibb Company | Způsoby léčení zánětlivých a imunitních nemocí za použití inhibitorů IkB kinázy (IKK) |
DE10112151A1 (de) | 2001-03-14 | 2002-09-19 | Merck Patent Gmbh | Substituierte Benzofuran-2-carbonsäureamide |
US20030045515A1 (en) | 2001-05-24 | 2003-03-06 | Lise Binderup | Combination medicament for treatment of neoplastic diseases |
CA2447021C (en) | 2001-05-24 | 2010-08-10 | Leo Pharma A/S | Pyridyl cyanoguanidine compounds |
WO2002094265A1 (en) | 2001-05-24 | 2002-11-28 | Leo Pharma A/S | A method of modulating nf-$g(k)b activity |
SE0102616D0 (sv) | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
SE0102617D0 (sv) | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
US20030127204A1 (en) | 2001-09-06 | 2003-07-10 | Varnell Daniel F. | Amphoteric polymer resins that increase the rate of sizing development |
US6849653B2 (en) | 2001-09-19 | 2005-02-01 | Pharmacia Corporation | Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation |
US20030109550A1 (en) | 2001-09-19 | 2003-06-12 | Michael Clare | Substituted indazole compounds for the treatment of inflammation |
CA2460939C (en) | 2001-09-19 | 2008-07-29 | Pharmacia Corporation | Substituted pyrazolyl compounds for the treatment of inflammation |
WO2003024935A2 (en) | 2001-09-19 | 2003-03-27 | Pharmacia Corporation | Substituted pyrazolyl compounds for the treatment of inflammation |
EP1444010A2 (en) | 2001-10-30 | 2004-08-11 | Pharmacia Corporation | Heteroaromatic carboxamide derivatives for the treatment of inflammation |
AU2003225580A1 (en) | 2002-02-19 | 2003-09-09 | Pharmacia Corporation | Tricyclic pyrazole derivatives for the treatment of inflammation |
EP1490371B1 (en) | 2002-04-03 | 2007-08-15 | Bristol-Myers Squibb Company | Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same |
MXPA04010952A (es) | 2002-05-09 | 2005-01-25 | Pharmacia Corp | Compuestos de pirazolilo sustituidos para el tratamiento de la inflamacion. |
EP1513516B1 (en) | 2002-06-06 | 2008-12-03 | Boehringer Ingelheim Pharmaceuticals Inc. | SUBSTITUTED 3-AMINO-THIENO(2,3-b) PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES |
US6900206B2 (en) * | 2002-06-20 | 2005-05-31 | Bristol-Myers Squibb Company | Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives |
DE10237722A1 (de) | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
BR0313923A (pt) | 2002-08-29 | 2005-07-12 | Boehringer Ingelheim Pharma | Derivados de 3-(sulfonamidoetil)-indol para uso como miméticos de glicocorticóide no tratamento de doenças inflamatórias, alérgicas e proliferativas |
SE0202693D0 (sv) * | 2002-09-11 | 2002-09-11 | Astrazeneca Ab | Compounds |
US6919334B2 (en) | 2002-09-12 | 2005-07-19 | Wyeth | Antidepressant azaheterocyclymethyl derivatives of 4,5-dihydroimidazo[1,4,5-de][1,4]benzoxazine |
US7135479B2 (en) | 2002-09-12 | 2006-11-14 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans |
US6911445B2 (en) | 2002-09-12 | 2005-06-28 | Wyeth | Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans |
DE10259244A1 (de) | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | N-(Indolethyl-)cycloamin-Verbindungen |
US7329668B2 (en) | 2003-02-25 | 2008-02-12 | Bristol-Myers Squibb Company | Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same |
GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
EP1651629A1 (en) | 2003-07-31 | 2006-05-03 | Boehringer Ingelheim Pharmaceuticals Inc. | Substituted benzothiophene compounds and uses thereof |
US7291733B2 (en) | 2003-10-10 | 2007-11-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted tricyclic heterocycles and their uses |
GB0400895D0 (en) * | 2004-01-15 | 2004-02-18 | Smithkline Beecham Corp | Chemical compounds |
TW200616967A (en) * | 2004-06-24 | 2006-06-01 | Smithkline Beecham Corp | Novel indazole carboxamides and their use |
WO2007005534A2 (en) * | 2005-06-30 | 2007-01-11 | Smithkline Beecham Corporation | Chemical compounds |
-
2005
- 2005-09-19 PE PE2005001077A patent/PE20060748A1/es not_active Application Discontinuation
- 2005-09-19 TW TW094132222A patent/TW200626142A/zh unknown
- 2005-09-20 AR ARP050103900A patent/AR054084A1/es unknown
- 2005-09-21 BR BRPI0515524-0A patent/BRPI0515524A/pt not_active IP Right Cessation
- 2005-09-21 KR KR1020077009055A patent/KR20070057969A/ko not_active Application Discontinuation
- 2005-09-21 MX MX2007003283A patent/MX2007003283A/es unknown
- 2005-09-21 JP JP2007532632A patent/JP2008513500A/ja active Pending
- 2005-09-21 US US11/575,416 patent/US7858796B2/en not_active Expired - Fee Related
- 2005-09-21 WO PCT/US2005/033752 patent/WO2006034317A2/en active Application Filing
- 2005-09-21 EP EP05798511A patent/EP1793826A4/en not_active Withdrawn
- 2005-09-21 SG SG200906215-9A patent/SG155932A1/en unknown
- 2005-09-21 CA CA002581180A patent/CA2581180A1/en not_active Abandoned
- 2005-09-21 AU AU2005286795A patent/AU2005286795A1/en not_active Abandoned
-
2007
- 2007-03-12 IL IL181877A patent/IL181877A0/en unknown
- 2007-03-29 MA MA29785A patent/MA28912B1/fr unknown
- 2007-04-18 NO NO20071988A patent/NO20071988L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2008513500A (ja) | 2008-05-01 |
TW200626142A (en) | 2006-08-01 |
BRPI0515524A (pt) | 2008-07-29 |
EP1793826A4 (en) | 2010-04-21 |
IL181877A0 (en) | 2007-07-04 |
WO2006034317A3 (en) | 2007-04-19 |
CA2581180A1 (en) | 2006-03-30 |
WO2006034317A2 (en) | 2006-03-30 |
SG155932A1 (en) | 2009-10-29 |
PE20060748A1 (es) | 2006-10-01 |
NO20071988L (no) | 2007-04-18 |
MA28912B1 (fr) | 2007-10-01 |
AU2005286795A1 (en) | 2006-03-30 |
KR20070057969A (ko) | 2007-06-07 |
US20070254873A1 (en) | 2007-11-01 |
EP1793826A2 (en) | 2007-06-13 |
MX2007003283A (es) | 2007-05-18 |
US7858796B2 (en) | 2010-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR054084A1 (es) | Derivados de indolcarboxamida y composiciones farmaceuticas que los contienen | |
JP2019530699A5 (es) | ||
AR110139A1 (es) | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV | |
EA202092899A1 (ru) | Гетероарильные соединения для лечения болезни гентингтона | |
RU2016118768A (ru) | Композиции, пригодные для лечения расстройств, связанных с kit | |
AR110782A1 (es) | Derivados de tirosinamida como inhibidores de rho-quinasa | |
JP2007522142A5 (es) | ||
JP2018529650A5 (es) | ||
UY29454A1 (es) | Derivados novedosos de 7-amino-(1,3) tiazol(4,5-d) pirimidina 5-sustituidos | |
AR080974A1 (es) | Derivados piridinicos y piperazinicos moduladores de la actividad de los canales del calcio activado por depositos intracelulares(soc), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y trastornos inmunes, entre otras. | |
AR052948A1 (es) | DERIVADOS DE ACETILENIL-PIRAZOLO-PIRIMIDINA COMO ANTAGONISTAS DE MGLUR2, METODOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU EMPLEO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES DEL SNC | |
AR073551A1 (es) | Pirimidinas macrociclicas como inhibidores de proteina cinasa | |
AR059380A1 (es) | Benzoimidazol-2-il pirimidinas y pirazinas como moduladores del receptor h4 de histamina, composiciones farmaceuticas | |
EA201391158A8 (ru) | Диаминиевые соли фенотиазина и их применение | |
NO20083567L (no) | Hydantoinderivater for behandling av inflammatoriske forstyrrelser | |
AR065804A1 (es) | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento | |
AR065622A1 (es) | Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona | |
CY1123285T1 (el) | Ενωσεις 6-αρυλ-4-(μορφολιν-4-υλ)-1η-πυριδιν-2-ονης χρησιμες για τη θεραπεια καρκινου και διαβητη | |
RU2017134551A (ru) | Новые дигидропиридоизохинолиноны и их фармацевтические композиции для лечения воспалительных расстройств | |
AR034555A1 (es) | Compuestos de 1,4-dihidropiridina como antagonistas de bradicinina; composicion farmaceutica, compuesto intermediario, procedimiento para preparar dichos compuestos | |
PE20200341A1 (es) | Composiciones y compuestos terapeuticos y metodos para utilizarlos | |
JP2019516713A5 (es) | ||
PH12017501428A1 (en) | 4-substituted benzoxaborole compounds and uses thereof | |
CL2020003227A1 (es) | Inhibidores de moléculas pequeñas de la familia de quinasas jak. | |
JP2021500340A5 (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |